A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Telaprevir
DRUG: Ribavirin
DRUG: Pegylated interferon alfa 2a

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]